Cargando…
Vaccination of boys or catch-up of girls above 11 years of age with the HPV-16/18 AS04-adjuvanted vaccine: where is the greatest benefit for cervical cancer prevention in Italy?
BACKGROUND: Since 2007, a Human Papillomavirus (HPV) vaccination programme against cervical cancer (CC) is implemented in Italy in 11-year-old girls. The extension of HPV vaccination to young adult women, or to 11-year-old boys could further reduce the CC burden, in the latter case from indirect eff...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4574450/ https://www.ncbi.nlm.nih.gov/pubmed/26381489 http://dx.doi.org/10.1186/s12879-015-1067-9 |
_version_ | 1782390631109230592 |
---|---|
author | Bonanni, Paolo Gabutti, Giovanni Demarteau, Nadia Boccalini, Sara La Torre, Giuseppe |
author_facet | Bonanni, Paolo Gabutti, Giovanni Demarteau, Nadia Boccalini, Sara La Torre, Giuseppe |
author_sort | Bonanni, Paolo |
collection | PubMed |
description | BACKGROUND: Since 2007, a Human Papillomavirus (HPV) vaccination programme against cervical cancer (CC) is implemented in Italy in 11-year-old girls. The extension of HPV vaccination to young adult women, or to 11-year-old boys could further reduce the CC burden, in the latter case from indirect effect on HPV transmission. The objective of the study was to compare the potential CC cases prevention from HPV-16/18 AS04-adjuvanted vaccination of adding catch-up targeting 15- or 25-year-old girls to the addition of boys vaccination in Italy. The models assessing the impact of these alternative vaccination strategies are usually dynamic models requiring numerous input data. Simpler models could however provide some insight into this question, as reported in the current study. METHODS: A published cohort model adapted to the Italian setting was used to estimate the potential CC reduction following different HPV vaccination strategies with a HPV-16/18 AS04-adjuvanted vaccine: vaccination of 11-year-old girls, female aged 15 or 25 years. The model assumed that the maximum benefit obtained from vaccinating boys equals the CC reduction that would result from immunisation of all non-vaccinated girls of the same age. Each cohort of 11-year-olds (either girls or boys) was assumed to include 281,000 individuals and a 70 % vaccination coverage was applied. Sensitivity analysis was performed by varying the vaccination coverage and the overlap in potential sexual contacts between vaccinated boys and girls of the same age-group. RESULTS: Under base case, compared with the screening-only scenario, HPV vaccination of 11-year-old girls, 15-year-old females, 25-year-old females or 11-year-old boys, would prevent 1,146, 1,082, 788 or 491 CC cases respectively. HPV vaccination of boys could result in more CC cases prevented than adding a female catch-up only in scenarios with low vaccination coverage in the primary target cohort and when combined with small overlap between vaccinated boys and girls of the same age cohort. CONCLUSIONS: For a fixed limited additional budget allowing the inclusion of a single catch-up cohort, the extension of HPV vaccination to girls or young women instead of boys was estimated to maximise the number of CC cases prevented. |
format | Online Article Text |
id | pubmed-4574450 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-45744502015-09-19 Vaccination of boys or catch-up of girls above 11 years of age with the HPV-16/18 AS04-adjuvanted vaccine: where is the greatest benefit for cervical cancer prevention in Italy? Bonanni, Paolo Gabutti, Giovanni Demarteau, Nadia Boccalini, Sara La Torre, Giuseppe BMC Infect Dis Research Article BACKGROUND: Since 2007, a Human Papillomavirus (HPV) vaccination programme against cervical cancer (CC) is implemented in Italy in 11-year-old girls. The extension of HPV vaccination to young adult women, or to 11-year-old boys could further reduce the CC burden, in the latter case from indirect effect on HPV transmission. The objective of the study was to compare the potential CC cases prevention from HPV-16/18 AS04-adjuvanted vaccination of adding catch-up targeting 15- or 25-year-old girls to the addition of boys vaccination in Italy. The models assessing the impact of these alternative vaccination strategies are usually dynamic models requiring numerous input data. Simpler models could however provide some insight into this question, as reported in the current study. METHODS: A published cohort model adapted to the Italian setting was used to estimate the potential CC reduction following different HPV vaccination strategies with a HPV-16/18 AS04-adjuvanted vaccine: vaccination of 11-year-old girls, female aged 15 or 25 years. The model assumed that the maximum benefit obtained from vaccinating boys equals the CC reduction that would result from immunisation of all non-vaccinated girls of the same age. Each cohort of 11-year-olds (either girls or boys) was assumed to include 281,000 individuals and a 70 % vaccination coverage was applied. Sensitivity analysis was performed by varying the vaccination coverage and the overlap in potential sexual contacts between vaccinated boys and girls of the same age-group. RESULTS: Under base case, compared with the screening-only scenario, HPV vaccination of 11-year-old girls, 15-year-old females, 25-year-old females or 11-year-old boys, would prevent 1,146, 1,082, 788 or 491 CC cases respectively. HPV vaccination of boys could result in more CC cases prevented than adding a female catch-up only in scenarios with low vaccination coverage in the primary target cohort and when combined with small overlap between vaccinated boys and girls of the same age cohort. CONCLUSIONS: For a fixed limited additional budget allowing the inclusion of a single catch-up cohort, the extension of HPV vaccination to girls or young women instead of boys was estimated to maximise the number of CC cases prevented. BioMed Central 2015-09-17 /pmc/articles/PMC4574450/ /pubmed/26381489 http://dx.doi.org/10.1186/s12879-015-1067-9 Text en © Bonanni et al. 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Bonanni, Paolo Gabutti, Giovanni Demarteau, Nadia Boccalini, Sara La Torre, Giuseppe Vaccination of boys or catch-up of girls above 11 years of age with the HPV-16/18 AS04-adjuvanted vaccine: where is the greatest benefit for cervical cancer prevention in Italy? |
title | Vaccination of boys or catch-up of girls above 11 years of age with the HPV-16/18 AS04-adjuvanted vaccine: where is the greatest benefit for cervical cancer prevention in Italy? |
title_full | Vaccination of boys or catch-up of girls above 11 years of age with the HPV-16/18 AS04-adjuvanted vaccine: where is the greatest benefit for cervical cancer prevention in Italy? |
title_fullStr | Vaccination of boys or catch-up of girls above 11 years of age with the HPV-16/18 AS04-adjuvanted vaccine: where is the greatest benefit for cervical cancer prevention in Italy? |
title_full_unstemmed | Vaccination of boys or catch-up of girls above 11 years of age with the HPV-16/18 AS04-adjuvanted vaccine: where is the greatest benefit for cervical cancer prevention in Italy? |
title_short | Vaccination of boys or catch-up of girls above 11 years of age with the HPV-16/18 AS04-adjuvanted vaccine: where is the greatest benefit for cervical cancer prevention in Italy? |
title_sort | vaccination of boys or catch-up of girls above 11 years of age with the hpv-16/18 as04-adjuvanted vaccine: where is the greatest benefit for cervical cancer prevention in italy? |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4574450/ https://www.ncbi.nlm.nih.gov/pubmed/26381489 http://dx.doi.org/10.1186/s12879-015-1067-9 |
work_keys_str_mv | AT bonannipaolo vaccinationofboysorcatchupofgirlsabove11yearsofagewiththehpv1618as04adjuvantedvaccinewhereisthegreatestbenefitforcervicalcancerpreventioninitaly AT gabuttigiovanni vaccinationofboysorcatchupofgirlsabove11yearsofagewiththehpv1618as04adjuvantedvaccinewhereisthegreatestbenefitforcervicalcancerpreventioninitaly AT demarteaunadia vaccinationofboysorcatchupofgirlsabove11yearsofagewiththehpv1618as04adjuvantedvaccinewhereisthegreatestbenefitforcervicalcancerpreventioninitaly AT boccalinisara vaccinationofboysorcatchupofgirlsabove11yearsofagewiththehpv1618as04adjuvantedvaccinewhereisthegreatestbenefitforcervicalcancerpreventioninitaly AT latorregiuseppe vaccinationofboysorcatchupofgirlsabove11yearsofagewiththehpv1618as04adjuvantedvaccinewhereisthegreatestbenefitforcervicalcancerpreventioninitaly |